Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 821

1.

Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.

Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L.

BMC Infect Dis. 2012 Sep 7;12:207. doi: 10.1186/1471-2334-12-207. Review.

2.

Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.

Sharma D, Baughman W, Holst A, Thomas S, Jackson D, da Gloria Carvalho M, Beall B, Satola S, Jerris R, Jain S, Farley MM, Nuorti JP.

Pediatr Infect Dis J. 2013 Feb;32(2):e45-53. doi: 10.1097/INF.0b013e3182788fdd.

PMID:
23080290
3.

Pneumococcal serotype evolution in Western Europe.

Tin Tin Htar M, Christopoulou D, Schmitt HJ.

BMC Infect Dis. 2015 Oct 14;15:419. doi: 10.1186/s12879-015-1147-x. Review.

4.

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.

Vaccine. 2013 Dec 16;31(52):6232-8. doi: 10.1016/j.vaccine.2013.10.032. Epub 2013 Oct 29.

PMID:
24176490
5.

Pneumococcal carriage and serotype variation before and after introduction of pneumococcal conjugate vaccines in patients with acute otitis media in Switzerland.

Allemann A, Frey PM, Brugger SD, Hilty M.

Vaccine. 2017 Apr 4;35(15):1946-1953. doi: 10.1016/j.vaccine.2017.02.010. Epub 2017 Mar 6.

6.

Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.

Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R.

Pediatr Infect Dis J. 2009 Apr;28(4):277-82. doi: 10.1097/INF.0b013e31818e0e2e.

PMID:
19258924
7.

Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US.

Shea KM, Weycker D, Stevenson AE, Strutton DR, Pelton SI.

Vaccine. 2011 Oct 19;29(45):8042-8. doi: 10.1016/j.vaccine.2011.08.057. Epub 2011 Aug 24.

PMID:
21871518
8.

Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.

Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA.

Clin Infect Dis. 2013 Oct;57(7):952-62. doi: 10.1093/cid/cit428. Epub 2013 Jun 26.

PMID:
23804191
9.

Epidemiology of Streptococcus pneumoniae causing acute otitis media among children in Southern Catalonia throughout 2007-2013: Incidence, serotype distribution and vaccine's effectiveness.

Ochoa-Gondar O, Figuerola-Massana E, Vila-Corcoles A, Aguirre CA, de Diego C, Satue E, Gomez F, Raga X; EPIVAC Study Group.

Int J Pediatr Otorhinolaryngol. 2015 Dec;79(12):2104-8. doi: 10.1016/j.ijporl.2015.09.022. Epub 2015 Sep 28.

PMID:
26453272
10.
11.

Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media.

Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E.

Pediatr Infect Dis J. 2012 Mar;31(3):297-301. doi: 10.1097/INF.0b013e318247ef84.

PMID:
22330166
12.

The rise and fall of pneumococcal serotypes carried in the PCV era.

Devine VT, Cleary DW, Jefferies JM, Anderson R, Morris DE, Tuck AC, Gladstone RA, O'Doherty G, Kuruparan P, Bentley SD, Faust SN, Clarke SC.

Vaccine. 2017 Mar 1;35(9):1293-1298. doi: 10.1016/j.vaccine.2017.01.035. Epub 2017 Feb 1.

PMID:
28161425
13.

Carriage of Streptoccoccus pneumoniae 7 years after implementation of vaccination program in a population with very high and long-lasting coverage, Italy.

Ansaldi F, de Florentiis D, Canepa P, Zancolli M, Martini M, Orsi A, Durando P, Icardi G.

Vaccine. 2012 Mar 16;30(13):2288-94. doi: 10.1016/j.vaccine.2012.01.067. Epub 2012 Feb 3.

PMID:
22306795
14.

A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation.

Cohen R, Varon E, Doit C, Schlemmer C, Romain O, Thollot F, Béchet S, Bonacorsi S, Levy C.

Vaccine. 2015 Sep 22;33(39):5118-26. doi: 10.1016/j.vaccine.2015.08.010. Epub 2015 Aug 11.

PMID:
26271823
15.

Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study.

Flasche S, Van Hoek AJ, Sheasby E, Waight P, Andrews N, Sheppard C, George R, Miller E.

PLoS Med. 2011 Apr;8(4):e1001017. doi: 10.1371/journal.pmed.1001017. Epub 2011 Apr 5.

16.

Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease.

Melegaro A, Choi YH, George R, Edmunds WJ, Miller E, Gay NJ.

BMC Infect Dis. 2010 Apr 8;10:90. doi: 10.1186/1471-2334-10-90.

17.

Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine.

Wroe PC, Lee GM, Finkelstein JA, Pelton SI, Hanage WP, Lipsitch M, Stevenson AE, Rifas-Shiman SL, Kleinman K, Dutta-Linn MM, Hinrichsen VL, Lakoma M, Huang SS.

Pediatr Infect Dis J. 2012 Mar;31(3):249-54. doi: 10.1097/INF.0b013e31824214ac.

18.

Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae.

Dagan R.

Clin Microbiol Infect. 2009 Apr;15 Suppl 3:16-20. doi: 10.1111/j.1469-0691.2009.02726.x. Review.

20.

Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden.

Galanis I, Lindstrand A, Darenberg J, Browall S, Nannapaneni P, Sjöström K, Morfeldt E, Naucler P, Blennow M, Örtqvist Å, Henriques-Normark B.

Eur Respir J. 2016 Apr;47(4):1208-18. doi: 10.1183/13993003.01451-2015. Epub 2016 Jan 21.

Supplemental Content

Support Center